3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Small Cell Lung Carcinoma
2
Neoplasms
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Merkel Cell
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Stomach Neoplasms
1
Sarcoma
1
Penile Neoplasms
1
PD-L1 Positive Mutation Tumor
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Myeloid, Chronic-Phase
1
Hodgkin Disease
1
Hemangiosarcoma
1
Glioblastoma
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Interventions
Paclitaxel
6
Carboplatin
6
Radiotherapy
5
olaparib
4
Surveys and Questionnaires
4
Cisplatin
4
Surgical Procedures, Operative
3
Sentinel Lymph Node Biopsy
3
Metformin
3
pembrolizumab
2
lenvatinib
2
durvalumab
2
dostarlimab
2
anlotinib
2
Reverse Transcriptase Polymerase Chain Reaction
2
Progesterone
2
Magnetic Resonance Spectroscopy
2
Injections
2
High-Energy Shock Waves
2
Hematologic Tests
2
Genetic Testing
2
Docetaxel
2
Blood Specimen Collection
2
Base Sequence
2
Amplified Fragment Length Polymorphism Analysis
2
vistusertib
1
serabelisib
1
pazopanib
1
palbociclib
1
onapristone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Endometrial Neoplasms
×
avelumab
×
Clear all
NCT03503786
2023-11-13
MITO END-3
National Cancer Institute, Naples
Phase 2
Unknown
125 enrolled